HomeAI · summaries
Storia in 2 fonti
'Immediately Practice-Changing' Lung Cancer Trial in Curative Setting
Substantial EFS improvement with selpercatinib in RET fusion-positive disease
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
medpagetoday.com
'Immediately Practice-Changing' Lung Cancer Trial in Curative Setting
Substantial EFS improvement with selpercatinib in RET fusion-positive disease
- ·
morningstar.com
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people…
Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung…